OCS
Oculis Holding AG Ordinary sharesNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.59B
P/E Ratio
—
EPS
$-2.36
Beta
0.21
52W High
$30.68
52W Low
$16.00
50-Day MA
$27.41
200-Day MA
$21.33
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Oculis Holding AG Ordinary shares
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company is headquartered in Zug, Switzerland.
Fundamentals
| Revenue (TTM) | $1.20M |
| Gross Profit (TTM) | $-55.89M |
| EBITDA | $-81.52M |
| Operating Margin | -5020.00% |
| Return on Equity | -73.50% |
| Return on Assets | -28.60% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $4.24 |
| Price-to-Book | 6.28 |
| Price-to-Sales (TTM) | 1322.18 |
| EV/Revenue | - |
| EV/EBITDA | -3.47 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 13600.00% |
| Shares Outstanding | $57.98M |
| Float | $49.97M |
| % Insiders | 4.27% |
| % Institutions | 52.60% |
Analyst Ratings
Consensus ($47.27 target)
3
Strong Buy7
BuyData last updated: 4/9/2026